MedPath

Dermira, Inc.

Dermira, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2010-01-01
Employees
333
Market Cap
-
Website
http://www.dermira.com

Clinical Trials

17

Active:7
Completed:10

Trial Phases

3 Phases

Phase 1:10
Phase 2:4
Phase 3:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials

Phase 1
10 (58.8%)
Phase 2
4 (23.5%)
Phase 3
3 (17.6%)

A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Phase 3
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Olumacostat Glasaretil Gel, 5.0%
First Posted Date
2017-04-25
Last Posted Date
2021-07-20
Lead Sponsor
Dermira, Inc.
Target Recruit Count
748
Registration Number
NCT03127956
Locations
🇺🇸

Avant Research Associates, LLC, Guntersville, Alabama, United States

🇺🇸

Advanced Research Associates, Glendale, Arizona, United States

🇺🇸

Alliance Dermatology & MOHS Center, Phoenix, Arizona, United States

and more 89 locations

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Phase 3
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Olumacostat Glasaretil Gel, 5.0%
Other: Olumacostat Glasaretil Gel, Vehicle
First Posted Date
2017-03-08
Last Posted Date
2021-07-20
Lead Sponsor
Dermira, Inc.
Target Recruit Count
744
Registration Number
NCT03073486
Locations
🇺🇸

Avant Research Associates, LLC, Guntersville, Alabama, United States

🇺🇸

Advanced Research Associates, Glendale, Arizona, United States

🇺🇸

Dermatology Trial Associates, Bryant, Arkansas, United States

and more 42 locations

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Phase 3
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Olumacostat Glasaretil Gel, 5.0%
Other: Olumacostat Glasaretil Gel, Vehicle
First Posted Date
2017-01-23
Last Posted Date
2021-07-20
Lead Sponsor
Dermira, Inc.
Target Recruit Count
759
Registration Number
NCT03028363
Locations
🇺🇸

Alliance Dermatology & MOHS Center, Phoenix, Arizona, United States

🇺🇸

Anaheim Clinical Trials, Anaheim, California, United States

🇺🇸

Dermatology Research Associates, Los Angeles, California, United States

and more 46 locations

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris

Phase 2
Completed
Conditions
Acne Vulgaris
Interventions
First Posted Date
2015-04-30
Last Posted Date
2021-07-20
Lead Sponsor
Dermira, Inc.
Target Recruit Count
420
Registration Number
NCT02431052
Locations
🇺🇸

Coastal Clinical Research, Inc., Mobile, Alabama, United States

🇺🇸

T. Joseph Raoof, MD, Inc., Encino, California, United States

🇺🇸

University Clinical Trials, Inc., San Diego, California, United States

and more 30 locations

A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Other: Vehicle
First Posted Date
2013-11-25
Last Posted Date
2021-07-20
Lead Sponsor
Dermira, Inc.
Target Recruit Count
23
Registration Number
NCT01993433
Locations
🇨🇦

Clinique Médicale Dr Isabelle Delorme, Drummondville, Quebec, Canada

🇨🇦

Innovaderm Research, Inc, Montreal, Quebec, Canada

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.